Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript
All right. Let's go ahead and get started. Thanks, everyone, for coming. This is the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Neurocrine, and presenting on behalf of the company, we have CEO, Kevin Gorman. Kevin?
Thank you, Anupam, and thank you, everyone, for being here today. I almost feel like I need to be running back and forth on here. Before I get started, I put up our safe harbor statement. I will be making forward-looking statements. What I want to accomplish this morning is to tell you about Neurocrine, how we -- what we look like today, what our philosophy is, what our strategy has been, that's got us here and where we see that strategy taking us throughout the rest of this decade.
And so if you look at what
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
